- Motley Fool•2 hours ago
Remicade, Xarelto, Imbruvica, Darzalex, and Stelara could have the biggest impact on Johnson & Johnson's top and bottom lines in 2017.
- Zacks•11 hours ago
Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.
- Financial Times•14 hours ago
Pfizer, the world's top drugmaker by revenues, has warned that a strengthening dollar would be "a very big challenge" for the company in 2017, raising concerns for US corporations that generate ...
JNJ : Summary for Johnson & Johnson Common Stock - Yahoo Finance
Johnson & Johnson (JNJ)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||114.41 - 115.10|
|52 Week Range||94.28 - 126.07|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.13|
|Dividend & Yield||3.20 (2.79%)|
|1y Target Est||N/A|